Human synaptotagmin-II is not a high affinity receptor for botulinum neurotoxin B and G: increased therapeutic dosage and immunogenicity
about
Current status and future directions of botulinum neurotoxins for targeting pain processingStructure of dual receptor binding to botulinum neurotoxin BCrystal Structures of Botulinum Neurotoxin DC in Complex with Its Protein Receptors Synaptotagmin I and IIBotulinum Neurotoxins Serotypes A and B induce paralysis of mouse striated and smooth muscles with different potencies.Diverse binding modes, same goal: The receptor recognition mechanism of botulinum neurotoxin.Qualitative and Quantitative Detection of Botulinum Neurotoxins from Complex Matrices: Results of the First International Proficiency Test.Progress in cell based assays for botulinum neurotoxin detectionBotulinum Neurotoxin Serotype A Recognizes Its Protein Receptor SV2 by a Different Mechanism than Botulinum Neurotoxin B Synaptotagmin.Embryonic Stem Cell-Derived Neurons Grown on Multi-Electrode Arrays as a Novel In vitro Bioassay for the Detection of Clostridium botulinum Neurotoxins.Components of the SNARE-containing regulon are co-regulated in root cells undergoing defense.Novel therapeutic uses and formulations of botulinum neurotoxins: a patent review (2012 - 2014).Development of an Innovative in Vitro Potency Assay for Anti-Botulinum Antitoxins.Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology.Engineered botulinum neurotoxin B with improved efficacy for targeting human receptorsA Cell Line for Detection of Botulinum Neurotoxin Type B.Botulinum Toxin in Aesthetic Medicine: Myths and Realities.Two Feet on the Membrane: Uptake of Clostridial Neurotoxins.The Expanding Therapeutic Utility of Botulinum Neurotoxins.Engineering Botulinum Toxins to Improve and Expand Targeting and SNARE Cleavage Activity
P2860
Q26778129-16B7CBA5-D930-4C06-B063-58B2E21E34E4Q27678834-D915FA45-985D-4B73-9CD6-1A7C315A35C4Q27679493-0DDA46B4-F8B3-4368-A26B-CA34FD79F157Q33771420-08D82B98-A193-4444-9AB1-FBA41DAF7FBFQ35563112-298933F3-E8FF-438D-B435-72FDBA2B7E43Q36401410-4DCBAA37-0CE9-4942-B20D-E20CEC43FA28Q36818335-788D23AA-9D5F-4A9F-9F0F-2655FBF9404EQ36946982-A8367F05-0624-497E-BAA1-94A27885C453Q37660850-A345309B-F789-4BEA-849D-C437290AADFFQ37701779-6911C317-828D-4193-A83B-388025648F2FQ38406085-A5FC3A8A-633F-4E20-B840-23DD7FF0312CQ38817600-E2397EC0-44D8-4E6C-9FD2-1DA73D7BD97EQ39207459-C9D062C6-5C1D-442B-AB4E-E000458568BCQ40971832-216E1C39-CFA0-4D88-922F-4795971C15CFQ47151324-743BFD44-2134-455D-B9F3-471F83AA1113Q47671772-990F0F66-2CC8-4123-BD2A-425AADFFA51FQ48026258-01990F91-1D38-469C-94FB-E0295345BE7EQ55105284-5B451618-511E-492D-B7AF-0746C1089498Q57177243-87334621-1EA4-4C56-B92F-68D0DCEB299A
P2860
Human synaptotagmin-II is not a high affinity receptor for botulinum neurotoxin B and G: increased therapeutic dosage and immunogenicity
description
2012 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2012
@ast
im Februar 2012 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 2012/02/17)
@sk
vědecký článek publikovaný v roce 2012
@cs
wetenschappelijk artikel (gepubliceerd op 2012/02/17)
@nl
наукова стаття, опублікована в лютому 2012
@uk
مقالة علمية (نشرت في 17-2-2012)
@ar
name
Human synaptotagmin-II is not ...... utic dosage and immunogenicity
@ast
Human synaptotagmin-II is not ...... utic dosage and immunogenicity
@en
Human synaptotagmin-II is not ...... utic dosage and immunogenicity
@nl
type
label
Human synaptotagmin-II is not ...... utic dosage and immunogenicity
@ast
Human synaptotagmin-II is not ...... utic dosage and immunogenicity
@en
Human synaptotagmin-II is not ...... utic dosage and immunogenicity
@nl
prefLabel
Human synaptotagmin-II is not ...... utic dosage and immunogenicity
@ast
Human synaptotagmin-II is not ...... utic dosage and immunogenicity
@en
Human synaptotagmin-II is not ...... utic dosage and immunogenicity
@nl
P2093
P2860
P3181
P1433
P1476
Human synaptotagmin-II is not ...... utic dosage and immunogenicity
@en
P2093
Andreas Rummel
Gesche Willjes
Jasmin Strotmeier
Thomas Binz
P2860
P304
P3181
P356
10.1016/J.FEBSLET.2011.12.037
P407
P577
2012-02-17T00:00:00Z